News|Videos|November 16, 2026

CTAD 2026 Preview: Clinical Trial Updates and Emerging Alzheimer Disease Research

Fact checked by: Marco Meglio

NeurologyLive's Louie Pasculli previews key clinical trial readouts, long-term treatment data, and emerging therapeutic approaches in Alzheimer disease ahead of CTAD 2026, held November 16-19 in Boston, Massachusetts. [WATCH TIME: 4 MINUTES]

With the 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference will take place November 16–19, 2026, in Boston, Massachusetts, and bring together researchers, clinicians, and industry representatives to discuss advances in Alzheimer's disease (AD) research and therapeutic development. The annual meeting provides a forum for sharing clinical trial findings, discussing emerging treatment strategies, and examining developments in disease monitoring and clinical research.

In this video, NeurologyLive's Louie Pasculli previews several key clinical trial updates and emerging research that clinicians could be on the lookout for during this year's meeting. The preview offers an overview of the research landscape heading into the conference and several developments that may help shape ongoing discussions around AD treatment and clinical research.

WATCH TIME: 4 minutes | Captions are auto-generated and may contain errors.

This video explores several areas of Alzheimer disease (AD) research expected to draw interest at CTAD 2026, including investigational therapies, longer-term treatment outcomes, and emerging approaches targeting different disease pathways. The meeting will also feature research on blood-based biomarkers, neuroimaging, proteomics, and AI. Presentations from clinicians, researchers, and other experts in the AD field will explore the potential applications of these approaches in patient identification, disease monitoring, and clinical trial development.

NeurologyLive will provide coverage throughout CTAD 2026, featuring updates on key research findings and clinical perspectives on developments across the AD research landscape. Coverage will include interviews with investigators and experts, along with reports highlighting notable data and discussions from the meeting.

Video Chapters:

  • 00:00 – Introduction and CTAD 2026 overview
  • 00:50 – Key clinical trial readouts: POLARIS-AD, PRImus-AD, and NTRX-07
  • 02:01 – Long-term treatment data: Clarity AD, LEADER, and CELIA
  • 02:57 – Emerging therapeutic approaches: trontinemab and posdinemab
  • 03:28 – Biomarkers, artificial intelligence, and clinical trial design
  • 03:58 – Closing and continued CTAD 2026 coverage

For continued coverage of CTAD 2026, click here!


Related to this article